Home
  • E-mailAurora.Martinez@uib.no
  • Phone+47 55 58 64 27
  • Visitor Address
    Jonas Lies vei 91
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen

Aurora Martinez is the leader of the research group Biorecognition that studies the relation between biomolecular structure and function to understand and develop new therapeutic options for genetic diseases, notably neurometabolic disorders such as phenylketonuria (PKU) and defects in dopamine synthesis.

Aurora is also a partner in the KG Jebsen Centre for neuropsychiatric disorders. In addition, she is also a partner in the project 'Molecular control of Arc protein: Decoding a master regulator of synaptic plasticity and cognition', coordinated by Clive Bramham, which received support from the Toppforsk Program (NFR).

  • Show author(s) (2024). Tetrahydrobiopterin (BH<inf>4</inf>) treatment stabilizes tyrosine hydroxylase: Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock-in mouse model. The Journal of Inherited Metabolic Disease (JIMD).
  • Show author(s) (2024). Mouse models for inherited monoamine neurotransmitter disorders. The Journal of Inherited Metabolic Disease (JIMD).
  • Show author(s) (2023). Towards the therapeutic correction of mitochondrial Complex I deficiency in dopaminergic cell models.
  • Show author(s) (2023). Screening for VMAT2 chaperones and activity modulators.
  • Show author(s) (2023). Potassium channels in behavioral brain disorders. Molecular mechanisms and therapeutic potential: A narrative review. Neuroscience and Biobehavioral Reviews.
  • Show author(s) (2023). One ring closer to a closure: the crystal structure of the ES<inf>3</inf> hydroxymethylbilane synthase intermediate. The FEBS Journal.
  • Show author(s) (2023). Impact of small molecule-mediated inhibition of ammonia detoxification on lung malignancies and liver metabolism. Cancer Communications. 508-512.
  • Show author(s) (2023). Effect of simulated saturation diving on dopamine synthesis regulation.
  • Show author(s) (2022). High-throughput screening for VMAT2 activity modulators.
  • Show author(s) (2022). High-affinity anti-Arc nanobodies provide tools for structural and functional studies. PLOS ONE. 33 pages.

More information in national current research information system (CRIStin)